UCB Presents New Three-Year P-III (BE BRIGHT) OLE Study Results of Bimekizumab for Plaque Psoriasis at EADV 2022
Shots:
- The P-III (BE BRIGHT) OLE study evaluating bimekizumab (320mg, q4w or q8w) in 1355 adult patients with mod. to sev. PsO. The results showed that 8 out of 10 patients maintained PASI 100 response & health-related QoL outcomes who achieved complete skin clearance (PASI 100) @16wks.
- In all bimekizumab-randomized patients in (BE SURE, BE VIVID and BE READY) studies & patients with (BE SURE & BE READY), 89.3% & 93.6% achieved PASI 100 @1yr. & 82.0% & 84.4% @3yr. among 16wk. PASI 100 responders; 96.5% & 98.9% achieved PASI ≤2 @1yr. & 94.2% & 96.8% @3yr.; 92.0% & 95.8% achieved DLQI 0/1 @1yr. & 88.0% & 92.5% @3yr.
- The pooled safety data from ~3yrs. of treatment in P-II/III trials showed bimekizumab was well tolerated with no new safety signals
Ref: PRNewswire | Image: UCB
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
